Complement Pharma is a biotech company developing new therapeutics that target the complement system, an important component of the immune system. With a focus on C6 we aim to fight neurodegeneration in indications like TBI, ALS and MS. Our promising pre-clinical data, shows safety and efficacy of C6 inhibition to modify disease progression in the mentioned indications and beyond. Our first antibody, with excellent characteristics is now getting ready for GMP production and clinical trials. In June 2018 Alexion and Complement Pharma announced their collaboration to develop C6 complement inhibitor CP010 for neurodegenerative disorders.